Aziyo Biologics, Inc. (AZYO)
|Net Income (ttm)||-15.63M|
|Trading Day||January 25|
|Day's Range||14.48 - 16.42|
|52-Week Range||10.77 - 16.42|
SILVER SPRING, Md., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differen...
SILVER SPRING, Md., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differen...
Aziyo Biologics, a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo, a biological envelope that remodels into vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic devices; and ProxiCor, Tyke, and VasCure, which are a portfolio of extracellular matrices that retain the natural composition of colla... [Read more...]
|IPO Date |
Oct 8, 2020
Ronald K. Lloyd
|Stock Exchange |
|Ticker Symbol |
In 2019, AZYO's revenue was $42.90 million, an increase of 9.90% compared to the previous year's $39.04 million. Losses were -$11.94 million, 3.22% more than in 2018.
According to 4 analysts, the average rating for AZYO stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 25.00% from the latest price.